Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Can the new weight-loss drugs replace diet and exercise? What are the risks of GLP-1 medicines? Can the new weight-loss drugs replace diet and exercise? Aaron Luna and our expert panel explore ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

Can the new weight-loss drugs replace diet and exercise? Aaron Luna and our expert panel explain. Can the new weight-loss drugs replace diet and exercise? Aaron Luna and our expert panel explore ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.